RxDoctor Payments Data

Jamie Endt, NP

Family · Biloxi, MSNPI 1245967918

Payments from drug & device makers

$3,810in general payments, 2019–2025

Across 184 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$600
  • Novartis$523
  • Merck$409
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$290
  • Boehringer Ingelheim$269
  • Baxter Healthcare$238
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,57394%
  • Other$2386%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,810 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$33,133
Medicare patients
279
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$69,573
XareltoRivaroxaban41$47,207
EntrestoSacubitril/Valsartan35$42,600
JardianceEmpagliflozin22$25,353
Repatha SureclickEvolocumab23$16,949
BrilintaTicagrelor14$12,236
Metoprolol Succinate141$2,173
Potassium Chloride95$1,684
Ezetimibe88$1,684
Rosuvastatin Calcium107$1,641
Valsartan67$1,544
Prasugrel Hcl13$1,523
Atorvastatin Calcium144$1,413
ClopidogrelClopidogrel Bisulfate98$1,087
Amlodipine Besylate162$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$69,57386 claims
Johnson & JohnsonXarelto$216$47,20741 claims
NovartisEntresto$523$42,60035 claims
Boehringer IngelheimJardiance$269$25,35322 claims
AstraZenecaBrilinta$63$12,23614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →